CClinicalTrials.gg
Status unknownNCT01098929Updated Dec 17, 2015

Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia

An observational study in Congenital Diaphragmatic Hernia, sponsored by Massachusetts General Hospital. Status unknown at 1 site in United States. Per ClinicalTrials.gov, last updated 2015-12-17.

Sponsored by Massachusetts General Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2015), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Study summary

Congenital diaphragmatic hernia (CDH) occurs when the diaphragm, the muscle that separates the chest cavity from the abdominal cavity, does not form properly. When an opening is present in the diaphragm, organs that are normally found in the abdomen can move up into the chest cavity. The primary objective of this study is to generate information about the hereditary basis of congenital diaphragmatic hernia and abnormal lung development. Our long-term goal is to identify ways to treat babies in utero with effective but safe drugs to speed up lung development before birth.

Read the detailed description

This study uses a combination of clinical, molecular biological, and developmental strategies to better understand the genetic basis of congenital diaphragmatic hernia. Ongoing projects at Massachusetts General Hospital include identification of novel genes affecting diaphragm and lung development in a) mouse models using laser capture, microdissection, expression arrays, and statistical and bioinformatics analysis and b) human kindreds with multiple affected family members using linkage analysis and exome sequencing.

Research projects based at Children's Hospital Boston include a) continued recruitment of a population of patients with congenital diaphragmatic hernia who are carefully phenotyped for entry into an extensive database, b) collection of biological samples belonging to the phenotyped cohort of patients, c) next-generation sequencing on candidate genes and d) molecular cytogenetic studies such as comparative genomic hybridization and subtelomeric fluorescence in situ hybridization.

Over 500 patients with congenital diaphragmatic hernia and their families have been recruited to date and efforts are ongoing to double this number. The investigators hope that the information gained through identifying the genes that contribute to congenital diaphragmatic hernia will provide the foundation for future efforts to develop effective interventions for the treatment of this disease.

02

Conditions studied

  • Congenital Diaphragmatic Hernia

Keywords

  • genes
  • genetic
  • chromosome
  • chromosome microarray
03

In context

Hernias, Diaphragmatic, Congenital

93 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 78 across 25 observational studies indexed under Hernias, Diaphragmatic, Congenital.

Browse Hernias, Diaphragmatic, Congenital studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children/infants with a congenital diaphragmatic hernia

Women who are currently pregnant with a fetus diagnosed with congenital diaphragmatic hernia

Individuals with a family history of congenital diaphragmatic hernia

Inclusion criteria

All individuals affected with a congenital diaphragmatic hernia (CDH), or with a family history of CDH

Exclusion criteria

Exclusion Criteria:

Individuals with no personal or family history of a CDH

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Congenital Diaphragmatic Hernia (CDH)

    Individuals affected with congenital diaphragmatic hernia (CDH)

  • Unaffected

    Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)

06

What researchers measure

Primary outcomes

  1. identify genes associated with CDH

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital Boston
    Boston, Massachusetts 02215, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01098929
Lead sponsor
Massachusetts General Hospital
Collaborators
Boston Children's Hospital
Responsible party
Patricia Donahoe, MD (Principal Investigator and Program Director, Pediatric Surgical Research Laboratories, Massachusetts General Hospital) — Principal investigator
First posted
Apr 5, 2010
Start date
Jul 2002
Primary completion
Jul 2017 (estimated)
Completion
Jul 2017 (estimated)
Last update
Dec 17, 2015

Study contacts

Jessica Kim, BS
Contact
jessica.kim2@childrens.harvard.edu
617-355-2555
Patricia Donahoe, MD
principal investigator · Massachusetts General Hospital
Jay Wilson, MD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion